{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T18:51:38Z","timestamp":1793731898622,"version":"4.6.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T00:00:00Z","timestamp":1763769600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T00:00:00Z","timestamp":1763769600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Nabiqasim Industries (Private) Limited"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"DOI":"10.1186\/s12882-025-04526-0","type":"journal-article","created":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T01:44:22Z","timestamp":1763775862000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparative efficacy and safety of finerenone in diabetic kidney disease: a meta-analysis of Asian and non-Asian populations"],"prefix":"10.1186","volume":"26","author":[{"given":"Syed Abbas","family":"Raza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aziz-Ur","family":"Rehman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azizul Hasan","family":"Aamir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisal","family":"Qureshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abaidullah","family":"Sajid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tariq","family":"Waseem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Sajid Rafiq","family":"Abbasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fawad","family":"Farooq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajkumar","family":"Sachdewani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umar Yousaf","family":"Raja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Akram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uneeba","family":"Syed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somia","family":"Iqtadar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahid","family":"Nabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aizaz","family":"Mand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooran","family":"Mal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Tahir","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aftab","family":"Mohsin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bilal","family":"Mohydin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aisha","family":"Sheikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azra","family":"Rizwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8784-0122","authenticated-orcid":false,"given":"Mehwish","family":"Mushtaq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,22]]},"reference":[{"key":"4526_CR1","unstructured":"IDF F. International diabetes. diabetes atlas 10th. 2021."},{"key":"4526_CR2","unstructured":"Foundation NK. Quick facts about kidney disease. 2022."},{"key":"4526_CR3","unstructured":"Fund AK. Kidney disease statistics. 2022."},{"key":"4526_CR4","doi-asserted-by":"publisher","first-page":"672350","DOI":"10.3389\/fendo.2021.672350","volume":"12","author":"Y Deng","year":"2021","unstructured":"Deng Y, Li N, Wu Y, Wang M, Yang S, Zheng Y, et al. Global, regional, and National burden of diabetes-related chronic kidney disease from 1990 to 2019. Front Endocrinol. 2021;12:672350.","journal-title":"Front Endocrinol"},{"key":"4526_CR5","doi-asserted-by":"publisher","first-page":"1195167","DOI":"10.3389\/fendo.2023.1195167","volume":"14","author":"Y Tateyama","year":"2023","unstructured":"Tateyama Y, Shimamoto T, Uematsu MK, Taniguchi S, Nishioka N, Yamamoto K, et al. Status of screening and preventive efforts against diabetic kidney disease between 2013 and 2018: analysis using an administrative database from Kyoto-city, Japan. Front Endocrinol (Lausanne). 2023;14:1195167.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"4526_CR6","doi-asserted-by":"publisher","first-page":"e54429","DOI":"10.2196\/54429","volume":"10","author":"L Shi","year":"2024","unstructured":"Shi L, Xue Y, Yu X, Wang Y, Hong T, Li X, et al. Prevalence and risk factors of chronic kidney disease in patients with type 2 diabetes in china: Cross-Sectional study. JMIR Public Health Surveill. 2024;10:e54429.","journal-title":"JMIR Public Health Surveill"},{"issue":"12","key":"4526_CR7","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1056\/NEJMoa011303","volume":"345","author":"EJ Lewis","year":"2001","unstructured":"Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist Irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345(12):851\u201360.","journal-title":"N Engl J Med"},{"issue":"9","key":"4526_CR8","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S2213-8587(15)00293-4","volume":"3","author":"D The Lancet","year":"2015","unstructured":"The Lancet D, amp, Endocrinology. Diabetic kidney disease: what does the next era hold? Lancet Diabetes Endocrinol. 2015;3(9):665.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"4526_CR9","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1053\/j.ajkd.2017.10.026","volume":"71","author":"K Umanath","year":"2018","unstructured":"Umanath K, Lewis JB. Update on diabetic nephropathy: core curriculum 2018. Am J Kidney Dis. 2018;71(6):884\u201395.","journal-title":"Am J Kidney Dis"},{"issue":"15","key":"4526_CR10","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJ Heerspink","year":"2020","unstructured":"Heerspink HJ, Stef\u00e1nsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou F-F, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436\u201346.","journal-title":"N Engl J Med"},{"issue":"11","key":"4526_CR11","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1093\/ajh\/hpy120","volume":"31","author":"M Buonafine","year":"2018","unstructured":"Buonafine M, Bonnard B, Jaisser F. Mineralocorticoid receptor and cardiovascular disease. Am J Hypertens. 2018;31(11):1165\u201374.","journal-title":"Am J Hypertens"},{"issue":"1","key":"4526_CR12","doi-asserted-by":"publisher","first-page":"T35","DOI":"10.1530\/JOE-16-0669","volume":"234","author":"S Shibata","year":"2017","unstructured":"Shibata S. 30 years of the mineralocorticoid receptor: mineralocorticoid receptor and NaCl transport mechanisms in the renal distal nephron. J Endocrinol. 2017;234(1):T35\u201347.","journal-title":"J Endocrinol"},{"issue":"1","key":"4526_CR13","doi-asserted-by":"publisher","first-page":"T125","DOI":"10.1530\/JOE-16-0600","volume":"234","author":"P Kolkhof","year":"2017","unstructured":"Kolkhof P, B\u00e4rfacker L. 30 YEARS OF THE MINERALOCORTICOID RECEPTOR: mineralocorticoid receptor antagonists: 60 years of research and development. J Endocrinol. 2017;234(1):T125\u201340.","journal-title":"J Endocrinol"},{"issue":"23","key":"4526_CR14","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219\u201329.","journal-title":"N Engl J Med"},{"issue":"47","key":"4526_CR15","doi-asserted-by":"publisher","first-page":"4789","DOI":"10.1093\/eurheartj\/ehab725","volume":"42","author":"G Liuzzo","year":"2021","unstructured":"Liuzzo G, Volpe M. FIGARO-DKD adds new evidence to the cardiovascular benefits of finerenone across the spectrum of patients with type 2 diabetes and chronic kidney disease. Eur Heart J. 2021;42(47):4789\u201390.","journal-title":"Eur Heart J"},{"issue":"6","key":"4526_CR16","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1002\/ejhf.2469","volume":"24","author":"G Filippatos","year":"2022","unstructured":"Filippatos G, Pitt B, Agarwal R, Farmakis D, Ruilope LM, Rossing P, et al. Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO-DKD trial. Eur J Heart Fail. 2022;24(6):996\u20131005.","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"4526_CR17","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","volume":"43","author":"R Agarwal","year":"2022","unstructured":"Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022;43(6):474\u201384.","journal-title":"Eur Heart J"},{"issue":"5s","key":"4526_CR18","first-page":"S1","volume":"102","author":"KDIGO","year":"2022","unstructured":"KDIGO. Clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2022;102(5s):S1\u2013127.","journal-title":"Kidney Int"},{"issue":"9\u201310","key":"4526_CR19","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1159\/000532102","volume":"54","author":"D Koya","year":"2023","unstructured":"Koya D, Anker SD, Ruilope LM, Rossing P, Liu Z, Lee BW, et al. Cardiorenal outcomes with finerenone in Asian patients with chronic kidney disease and type 2 diabetes: A FIDELIO-DKD post hoc analysis. Am J Nephrol. 2023;54(9\u201310):370\u20138.","journal-title":"Am J Nephrol"},{"issue":"6","key":"4526_CR20","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1159\/000531997","volume":"9","author":"H Zhang","year":"2023","unstructured":"Zhang H, Xie J, Hao C, Li X, Zhu D, Zheng H, et al. Finerenone in patients with chronic kidney disease and type 2 diabetes: the FIDELIO-DKD subgroup from China. Kidney Dis. 2023;9(6):498\u2013506.","journal-title":"Kidney Dis"},{"issue":"4","key":"4526_CR21","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.jdiacomp.2016.11.021","volume":"31","author":"S Katayama","year":"2017","unstructured":"Katayama S, Yamada D, Nakayama M, Yamada T, Myoishi M, Kato M, et al. A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy. J Diabetes Complicat. 2017;31(4):758\u201365.","journal-title":"J Diabetes Complicat"},{"key":"4526_CR22","doi-asserted-by":"crossref","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372.","DOI":"10.1136\/bmj.n71"},{"issue":"12","key":"4526_CR23","doi-asserted-by":"publisher","first-page":"100730","DOI":"10.1016\/j.xkme.2023.100730","volume":"5","author":"JM Flack","year":"2023","unstructured":"Flack JM, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Finerenone in black patients with type 2 diabetes and CKD: A post hoc analysis of the pooled FIDELIO-DKD and FIGARO-DKD trials. Kidney Med. 2023;5(12):100730.","journal-title":"Kidney Med"},{"issue":"10","key":"4526_CR24","doi-asserted-by":"publisher","first-page":"100704","DOI":"10.1016\/j.xkme.2023.100704","volume":"5","author":"SE Rosas","year":"2023","unstructured":"Rosas SE, Ruilope LM, Anker SD, Pitt B, Rossing P, Bonfanti AAC, et al. Finerenone in Hispanic patients with CKD and type 2 diabetes: A post hoc FIDELITY analysis. Kidney Med. 2023;5(10):100704.","journal-title":"Kidney Med"},{"issue":"24","key":"4526_CR25","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","volume":"385","author":"B Pitt","year":"2021","unstructured":"Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385(24):2252\u201363.","journal-title":"N Engl J Med"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04526-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-025-04526-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04526-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T07:23:28Z","timestamp":1764228208000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-025-04526-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,22]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4526"],"URL":"https:\/\/doi.org\/10.1186\/s12882-025-04526-0","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,22]]},"assertion":[{"value":"28 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This meta-analysis was conducted using only previously published data and did not involve direct interaction with human participants. Therefore, ethics approval from an institutional review board (IRB) or ethics committee was not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. This study did not include any individual patient data or identifiable images. All data were obtained from published, de-identified sources.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"676"}}